All In Biotech

Drug Trial Radar · NCT04657068

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

542

Planned (sponsor's estimate)

Start

Jan 27, 2021

Primary completion

Jan 2028

Study completion Jun 2028

Sponsor

Lead sponsor
Artios Pharma LtdIndustry
Sponsor type
Industry
First posted
Dec 8, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more about the side effects of ART0380 alone and in combination with gemcitabine or irinotecan * Learn more about the effectiveness of ART0380 alone and in combination with gemcitabine or irinotecan

Conditions

  • Advanced Cancer
  • Metastatic Cancer
  • Ovarian Cancer
  • Primary Peritoneal Cancer
  • Fallopian Tube Cancer
  • Endometrial Cancer
  • Metastatic Colorectal Cancer
  • Pancreatic Ductal Adenocarcinoma
  • Acinar Cell Carcinoma

Interventions

  • ART0380Drug

    Participants will receive ART0380 by mouth either intermittently (either once daily 3 days on, 4 days off; days 2-4 and 9-11;or days 1-3 and 8-10) or continuously (once daily each day) in 21 day cycles.

  • GemcitabineDrug

    Gemcitabine will be administered on Days 1 and 8 of a 21-day cycle.

  • IrinotecanDrug

    Irinotecan will be administered as a 90-minute infusion on Days 1 and 8 of a 21 day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Maximum tolerated dose (MTD) by the number of participants with dose limiting toxicities (DLTs) from ART0380 monotherapy and in combination with gemcitabine or irinotecanTime frame: From Cycle 0 Day -2 to Cycle 1 Day 21. Each cycle is 21 days.
  2. Parts B1/B3/B4: Number of participants with adverse events following administration of ART0380 monotherapy and/or in combination with irinotecan at RP2Ds.Time frame: From Cycle 1 Day 1 until up to 30 days after the last dose of ART0380. Each cycle is 21 days.
  3. Part B2: Progression free survival by RECIST 1.1 in participants receiving ART0380 in combination with gemcitabine or gemcitabine aloneTime frame: Every 6 weeks from Cycle 1 Day 1 for 18 weeks, then every 9 weeks up to approximately 24 months. Each cycle is 21 days.
  4. Parts B5/B6: Object Response Rate (ORR) based on RECIST 1.1 to access anti-tumor activity of ART0380 in combination with irinotecan in each cohort.Time frame: Every 6 weeks from Cycle 1 Day 1, until disease progression or death or start of a new anti-cancer therapy, up to 2 years. Each Cycle is 21 days.

Locations

88 sites in 4 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • Mayo Clinic (Arizona)

    Scottsdale, Arizona · Recruiting

  • University of Arkansas - Winthrop P. Rockefeller Cancer Institute

    Little Rock, Arkansas · Completed

  • USC Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • Sansum Clinic

    Santa Barbara, California · Active not recruiting

  • Providence Medical Foundation

    Santa Rosa, California · Recruiting

  • Rocky Mountain Cancer Center

    Denver, Colorado · Active not recruiting

  • Sarah Cannon Research Institute at HealthONE

    Denver, Colorado · Recruiting

  • The Sidney Kimmel Comprehensive Cancer Center (Johns Hopkins)

    Washington D.C., District of Columbia · Recruiting

  • Florida Cancer Specialists

    Fort Myers, Florida · Recruiting

  • Mayo Clinic (Florida)

    Jacksonville, Florida · Recruiting

  • Cancer Specialists of North Florida

    Jacksonville, Florida · Active not recruiting

  • Florida Cancer Specialists

    Orlando, Florida · Completed

  • Florida Cancer Specialists

    Sarasota, Florida · Active not recruiting

  • Florida Cancer Specialists

    West Palm Beach, Florida · Active not recruiting

  • Hope and Healing Cancer Services

    Hinsdale, Illinois · Active not recruiting

  • Community Health Network

    Indianapolis, Indiana · Recruiting

  • Our Lady of the Lake

    Baton Rouge, Louisiana · Completed

  • Maryland Oncology Hematology - Primary

    Columbia, Maryland · Active not recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Minnesota Oncology Hematology

    Maple Grove, Minnesota · Recruiting

  • Mayo Clinic (Minnesota)

    Rochester, Minnesota · Recruiting

  • Washington University

    St Louis, Missouri · Recruiting

  • Hematology Oncology Associates of Central New York

    East Syracuse, New York · Recruiting

  • Northwell Health Cancer Institute

    Lake Success, New York · Recruiting

  • Memorial Sloan-Kettering Cancer Center

    New York, New York · Recruiting

  • Oncology Hematology Care Primary

    Cincinnati, Ohio · Recruiting

  • Taylor Cancer Research Center

    Maumee, Ohio · Recruiting

  • Stephenson Cancer Center

    Oklahoma City, Oklahoma · Recruiting

  • Oregon Health & Science University

    Portland, Oregon · Recruiting

  • University of Pennsylvania / Abramson Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Research Organization

    Philadelphia, Pennsylvania · Recruiting

  • Tennessee Oncology, PLLC

    Chattanooga, Tennessee · Completed

  • Baptist Cancer Center

    Memphis, Tennessee · Completed

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • Vanderbilt Medical Center

    Nashville, Tennessee · Recruiting

  • Texas Oncology - Central/South Texas

    Austin, Texas · Active not recruiting

  • Mary Crowley Cancer Research

    Dallas, Texas · Recruiting

  • Texas Oncology - Baylor Charles A. Sammons Cancer Center

    Dallas, Texas · Active not recruiting

  • University of Texas Southwestern

    Dallas, Texas · Recruiting

Showing 40 of 88 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.